证券代码：301075 证券简称：多瑞医药 公告编号：2025-103 西藏多瑞医药股份有限公司 关于控股股东及其一致行动人协议转让股份事项取得确认书 暨控制权拟发生变更的进展公告 要约，承诺以上预受要约均为不可撤回且在要约收购期间不得处分。 自协议转让股份过户完成之日至要约收购完成之日，西藏嘉康放弃前 述承诺预受要约 19,440,000 股（占上市公司股份总数的 24.30%）的 表决权。 2025 年 11 月 10 日，西藏嘉康及及其一致行动人舟山清畅与王 庆太及其一致行动人崔子浩、曹晓兵签署了《股份转让协议之补充协 议》，对《股份转让协议》的部分条款进行调整。 本次权益变动后，王庆太、崔子浩、曹晓兵合计将拥有上市公司 29.60%的股份及该等股份对应的表决权，西藏嘉康、舟山清畅合计拥 有上市公司 11.98%的表决权，上市公司控股股东、实际控制人变更 为王庆太、崔子浩、曹晓兵。 具体内容详见公司于 2025 年 10 月 14 日、2025 年 11 月 11 日在 巨潮资讯网（www.cninfo.com.cn）披露的《关于控股股东及其一致行 动人协议转让股份暨控制权拟发生变更的提示性公告》（公告 ...

Core Viewpoint - Duory Pharmaceutical (301075.SZ) has indicated on its interactive platform that the company has not yet developed any products related to influenza medications [1] Group 1 - The company has no current product offerings in the influenza medication sector [1]

Core Viewpoint - The A-share market is seeing active trading in flu-related stocks, driven by an early peak in respiratory syncytial virus (RSV) and flu activity in China, as reported by the National Disease Control [1][2]. Group 1: Market Activity - Aipeng Medical has risen over 10%, while Panlong Pharmaceutical has reached a 10% limit up, with other companies like Rejing Bio and Dongfang Bio also seeing significant gains [1]. - The latest flu monitoring report indicates an increase in flu activity in southern provinces and a rise in northern provinces during the 44th week of 2025 [1]. Group 2: Key Data on Stocks - Aipeng Medical (300753) has a market cap of 3.969 billion and a year-to-date increase of 79.09% [2]. - Panlong Pharmaceutical (002864) has a market cap of 3.788 billion and a year-to-date increase of 18.84% [2]. - Rejing Bio (688068) has a market cap of 14 billion and a year-to-date increase of 144.44% [2]. - Dongfang Bio (688298) has a market cap of 5.836 billion with a slight year-to-date decrease of 1.30% [2]. - Other notable stocks include Te Yi Pharmaceutical (002728) with a market cap of 6.961 billion and a year-to-date increase of 52.45% [2].

Group 1 - The core viewpoint of the news is that Duorui Pharmaceutical has shown significant fluctuations in its financial performance and trading activities, with a notable decrease in revenue and net profit in the recent reporting period [1][2]. Group 2 - On November 11, Duorui Pharmaceutical's stock price increased by 0.02%, with a trading volume of 89.78 million yuan. The financing buy-in amount for the day was 12.24 million yuan, while the financing repayment was 11.49 million yuan, resulting in a net financing buy-in of 0.75 million yuan [1]. - As of November 11, the total financing and securities lending balance for Duorui Pharmaceutical was 190 million yuan, which accounts for 4.20% of its circulating market value, indicating a high level of financing compared to the past year [1]. - The company has not engaged in any securities lending activities on November 11, with both the securities lending repayment and selling amount recorded as zero [1]. - Duorui Pharmaceutical, established on December 22, 2016, and listed on September 29, 2021, focuses on the research, production, and sales of chemical drug formulations and their raw materials. The revenue composition is as follows: formulations 37.60%, intermediates 35.78%, raw materials 21.64%, and others 4.98% [1]. Group 3 - As of September 30, the number of shareholders for Duorui Pharmaceutical was 6,361, a decrease of 16.60% from the previous period. The average circulating shares per person increased by 19.90% to 12,576 shares [2]. - For the period from January to September 2025, Duorui Pharmaceutical reported a revenue of 137 million yuan, a year-on-year decrease of 31.68%. The net profit attributable to the parent company was -79.73 million yuan, reflecting a significant year-on-year decline of 366.82% [2]. - Since its A-share listing, Duorui Pharmaceutical has distributed a total of 59.87 million yuan in dividends, with 9.87 million yuan distributed over the past three years [2].

Group 1 - The core point of the article is that Duori Pharmaceutical announced a change in control, with three individuals forming a concerted action relationship to acquire a total of 23.68 million shares, representing 29.60% of the total share capital, at a price of 32.064 yuan per share, totaling 759 million yuan [1] - After the completion of this equity change, the three individuals will become the new actual controllers of the company, with Cui Zihao holding 14.90% of the shares as the largest shareholder, Wang Qingtai holding 5.00%, and Cao Xiaobing holding 9.70% [1] - The original shareholders, Xizang Jiakang and Deng Yong, have committed to renouncing their voting rights for 19.44 million shares (24.30% of the total share capital) until the completion of the tender offer [1] Group 2 - Wang Qingtai and Cao Xiaobing also plan to further increase their holdings through a partial tender offer for an additional 24.30% of the shares to solidify their control [1] - The equity change is still subject to the completion of share transfer registration and other procedures, meaning the change in control has not yet been finalized [1]

Core Viewpoint - The control of Duori Pharmaceutical has officially changed hands following a significant share transfer, impacting the company's governance structure and future direction [1] Share Transfer Details - Xizang Jiakang Times Technology Development Co., Ltd. and Zhoushan Qingchang Enterprise Management Partnership (Limited Partnership) collectively reduced their holdings by 23,680,000 shares, representing 29.60% of the total share capital [1] - The transfer price was set at 32.064 yuan per share, resulting in a total transaction value of 759 million yuan [1] - Post-transaction, the combined shareholding of the two entities decreased from 65.72% to 36.12% [1] Voting Rights and Control Change - Xizang Jiakang has relinquished voting rights associated with 19.44 million shares, which accounts for 24.30% of the total share capital [1] - The new shareholders, Wang Qingtai, Cui Zihao, and Cao Xiaobing, now hold a combined 29.60% stake and will exert control through board nominations and senior management arrangements [1] - The original actual controller, Deng Yong, is no longer recognized as the company's actual controller following this change [1] Future Plans - The information disclosure obligors have no plans to increase their holdings in the next 12 months but intend to partially reduce their shares through a tender offer [1]

西藏多瑞医药股份有限公司 详式权益变动报告书（修订稿） 上市公司名称：西藏多瑞医药股份有限公司 股票上市地点：深圳证券交易所 股票简称：多瑞医药 股票代码：301075 信息披露义务人一：王庆太 住所/通讯地址：河北省邢台市广宗县经济开发区创业大道南段东侧天王科技园 信息披露义务人二（信息披露义务人一之一致行动人）：崔子浩 住所/通讯地址：河北省邢台市任泽区荣御新天地 45 号楼 信息披露义务人三（信息披露义务人一之一致行动人）：曹晓兵 住所/通讯地址：北京市石景山区启迪香山 A 座 238 室 股份变动性质：股份增加（协议转让） 签署日期：二〇二五年十一月 1 西藏多瑞医药股份有限公司 详式权益变动报告书 修订说明 信息披露义务人已于 2025 年 10 月 14 日公告了《西藏多瑞医药股份有限公 司详式权益变动报告书》，现基于本次权益变动涉及的相关事项发生变化，信 息披露义务人对本次权益变动相关情况进行修订，本次主要修订内容如下。 一、根据本次权益变动相关方签署《股份转让协议之补充协议》的情况， 对相关内容进行修订及补充 详见本报告之"第一节 释义"、"第四节 权益变动 方式"之"三、本次权益变动相关协议 ...

国金证券股份有限公司 关于 西藏多瑞医药股份有限公司 详式权益变动报告书 之 财务顾问核查意见（修订稿） 财务顾问 （成都市青羊区东城根上街 95 号） 二〇二五年十一月 声 明 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司收购管 理办法》《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报 告书》《公开发行证券的公司信息披露内容与格式准则第 16 号——上市公司收购 报告书》等法律法规和规范性文件的规定，国金证券股份有限公司（以下简称"本 财务顾问"）按照证券行业公认的行业标准、道德规范，本着诚实信用、勤勉尽 责的态度，对本次权益变动的相关情况和资料进行了核查，对信息披露义务人出 具的《西藏多瑞医药股份有限公司详式权益变动报告书》所披露的内容出具核查 意见，以供投资者和有关各方参考。 为此，本财务顾问特作如下声明： 1、本财务顾问所依据的有关资料由信息披露义务人提供。信息披露义务人 已向本财务顾问保证，其所提供的出具本核查意见所依据的所有文件和材料是真 实、准确、完整、及时的，不存在任何重大遗漏、虚假记载或误导性陈述，并对 其真实性、准确性、完整性和合法性负责； 2、本财务 ...

西藏多瑞医药股份有限公司 简式权益变动报告书 （修订稿） 信息披露义务人二：舟山清畅企业管理合伙企业（有限合伙） 住所/通讯地址：中国（浙江）自由贸易试验区舟山市定海区北蝉乡（综保区） 舟山港综合保税区企业服务中心 305-64503 室 权益变动性质：股份减少（协议转让）、表决权放弃 签署日期：2025 年 11 月 修订说明 上市公司名称：西藏多瑞医药股份有限公司 股票上市地点：深圳证券交易所 股票简称：多瑞医药 股票代码：301075 信息披露义务人一：西藏嘉康时代科技发展有限公司 住所/通讯地址：西藏自治区昌都市经济开发区 A 区生物医药园一号楼 1 楼 1006 号仓库 信息披露义务人已于 2025 年 10 月 14 日公告了《西藏多瑞医药股份有限公 司简式权益变动报告书（西藏嘉康、舟山清畅）》，现基于本次权益变动涉及 的相关事项发生变化，信息披露义务人对本次权益变动相关情况进行修订，本 次主要修订内容如下： 一、根据本次权益变动相关方签署《股份转让协议之补充协议》的情况， 对相关内容进行修订及补充 详见本报告之"第四节 权益变动方式"之"三、《股份转让协议》的主要内 容"、"四、《股份转让协议之 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2025-101 西藏多瑞医药股份有限公司 关于控股股东及其一致行动人签署《股份转让协议之补充协议》 暨控制权拟发生变更的进展公告 公司控股股东西藏嘉康时代科技发展有限公司及其一致行动人 舟山清畅企业管理合伙企业（有限合伙）和受让方王庆太、崔子浩、 曹晓兵保证向本公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 一、基本情况概述 西藏多瑞医药股份有限公司（以下简称"多瑞医药"或"公司"）控 股股东西藏嘉康时代科技发展有限公司（以下简称"西藏嘉康"）及其 一致行动人舟山清畅企业管理合伙企业（有限合伙）（以下简称"舟山 清畅"）与受让方王庆太、崔子浩、曹晓兵于 2025 年 10 月 13 日签署 了《股份转让协议》。西藏嘉康及其一致行动人舟山清畅拟以协议转 让方式合计向王庆太及其一致行动人崔子浩、曹晓兵转让其持有的公 司无限售流通股 23,680,000 股（占公司总股本的 29.60%）。同时，王 庆太和曹晓兵拟通过部分要约收购的方式进一步增持上市公司的股 份， ...